Aurobindo Pharma announced that its subsidiary, CuraTeQ Biologics s.r.o., has received marketing authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Bevqolva, ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential to become new treatments.

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

This paper presents the important discovery that lipid metabolic imbalance caused by Snail, an EMT-related transcription factor, contributes to the acquisition of chemoresistance in cancer cells.

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...